Acuitas Therapeutics - Wikipedia Acuitas Therapeutics Inc is a Canadian biotechnology company based in Vancouver, British Columbia The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19 [1][2]
Acuitas Therapeutics - LinkedIn Acuitas Therapeutics Inc , the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech
Acuitas Small Cap Active ETF – Acuitas Funds, LLC Acuitas seeks to invest with complementary, return-focused small cap managers that will outperform their benchmarks over the long run Those managers are combined in a manner intended to reduce volatility while capturing the attractive returns available in active small cap
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid . . . Founded in February 2009, Vancouver-based Acuitas Therapeutics (www acuitastx com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles
Acuitas Therapeutics - White Rose Wiki Acuitas Therapeutics, originally called AlCana Technologies, is a Canadian biotechnology company based in Vancouver, British Columbia The company was co-founded by Pieter Cullis, Thomas Madden and Michael Hope